🇺🇸 FDA
Pipeline program

Semaglutide B 3.0 mg/ml PDS290

NOK0024 / Z2023097

Approved small_molecule active

Quick answer

Semaglutide B 3.0 mg/ml PDS290 for obesity is a Approved program (small_molecule) at Disc Medicine with 1 ClinicalTrials.gov record(s).

Program details

Company
Disc Medicine
Indication
obesity
Phase
Approved
Modality
small_molecule
Status
active

Clinical trials